| Name | Title | Contact Details |
|---|
Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.
BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
CTMG is a Greenville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Interface Biologics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Southwest Foundation For Biomedical Research is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.